These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11535198)

  • 21. HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy.
    Agosto LM; Uchil PD; Mothes W
    Trends Microbiol; 2015 May; 23(5):289-95. PubMed ID: 25766144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.
    Chun TW; Engel D; Berrey MM; Shea T; Corey L; Fauci AS
    Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8869-73. PubMed ID: 9671771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling the emergence of HIV-1 drug resistance resulting from antiretroviral therapy: insights from theoretical and numerical studies.
    Raimundo SM; Yang HM; Venturino E; Massad E
    Biosystems; 2012; 108(1-3):1-13. PubMed ID: 22155363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART.
    Sedaghat AR; Siliciano JD; Brennan TP; Wilke CO; Siliciano RF
    PLoS Pathog; 2007 Aug; 3(8):e122. PubMed ID: 17784786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-2 taken to HAART.
    Gilden D
    GMHC Treat Issues; 1999 Feb; 13(2):4-6. PubMed ID: 11366116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multidrug Therapy for HIV Infection: Dynamics of Immune System.
    Kamboj D; Sharma MD
    Acta Biotheor; 2019 Jun; 67(2):129-147. PubMed ID: 30515609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.
    Chun TW; Engel D; Mizell SB; Hallahan CW; Fischette M; Park S; Davey RT; Dybul M; Kovacs JA; Metcalf JA; Mican JM; Berrey MM; Corey L; Lane HC; Fauci AS
    Nat Med; 1999 Jun; 5(6):651-5. PubMed ID: 10371503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
    Finzi D; Hermankova M; Pierson T; Carruth LM; Buck C; Chaisson RE; Quinn TC; Chadwick K; Margolick J; Brookmeyer R; Gallant J; Markowitz M; Ho DD; Richman DD; Siliciano RF
    Science; 1997 Nov; 278(5341):1295-300. PubMed ID: 9360927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of target cell availability on HIV-1 production in vitro.
    Schwartz EJ; Neumann AU; Teixeira AV; Bruggeman LA; Rappaport J; Perelson AS; Klotman PE
    AIDS; 2002 Feb; 16(3):341-5. PubMed ID: 11834944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
    Autran B; Carcelain G; Li TS; Blanc C; Mathez D; Tubiana R; Katlama C; Debré P; Leibowitch J
    Science; 1997 Jul; 277(5322):112-6. PubMed ID: 9204894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toward HIV eradication or remission: the tasks ahead.
    Ho DD
    Science; 1998 Jun; 280(5371):1866-7. PubMed ID: 9669944
    [No Abstract]   [Full Text] [Related]  

  • 32. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral dynamics model with CTL immune response incorporating antiretroviral therapy.
    Wang Y; Zhou Y; Brauer F; Heffernan JM
    J Math Biol; 2013 Oct; 67(4):901-34. PubMed ID: 22930342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
    Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
    J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A delay-differential equation model of HIV infection of CD4(+) T-cells.
    Culshaw RV; Ruan S
    Math Biosci; 2000 May; 165(1):27-39. PubMed ID: 10804258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection.
    Dyrhol-Riise AM; Voltersvik P; Olofsson J; Asjö B
    AIDS; 1999 Dec; 13(17):2365-76. PubMed ID: 10597778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure.
    Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W
    Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315
    [No Abstract]   [Full Text] [Related]  

  • 38. HIV-1 and HAART: a time to cure, a time to kill.
    Saag MS; Kilby JM
    Nat Med; 1999 Jun; 5(6):609-11. PubMed ID: 10371490
    [No Abstract]   [Full Text] [Related]  

  • 39. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.
    Fraser C; Ferguson NM; Ghani AC; Prins JM; Lange JM; Goudsmit J; Anderson RM; de Wolf F
    AIDS; 2000 Apr; 14(6):659-69. PubMed ID: 10807189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART.
    Sanche S; Mesplède T; Sheehan NL; Li J; Nekka F
    PLoS One; 2018; 13(7):e0198090. PubMed ID: 30016329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.